Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA3 | P32297 | 2/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.45 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.41 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.41 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13835368 | 0.83 | ACVR1 (0.41) | ACVRL1ACVR1BMPR1BACVR1B | |
| SCHEMBL3662113 | 0.75 | CHRNA3 (0.51) | CHRNA3CHRNB2CHRNA4CHRNB1CHRNB4 | |
| SCHEMBL609618 | 0.75 | ABL1 (0.40) | CHRNA3CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL609693 | 0.75 | BTK (0.42) | ACVRL1ACVR1BMPR1BACVR1B | |
| Hydrochloric Acid SCHEMBL7674172 | 0.74 | CHRNA3 (0.50) | CHRNA3CHRNB2CHRNA4CHRNB1CHRNB4 | |
| Hydrochloric Acid SCHEMBL7663501 | 0.74 | CHRNA3 (0.50) | CHRNA3CHRNB2CHRNA4CHRNB1CHRNB4 | |
| SCHEMBL609721 | 0.73 | CHRNA3 (0.38) | CHRNA3CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL7417658 | 0.73 | LTA4H (0.56) | CHRNA3CHRNB2CHRNA4CHRNB1CHRNB4 | |
| SCHEMBL7462908 | 0.72 | CHRNA3 (0.51) | CHRNA3CHRNB2CHRNA4CHRNB1CHRNB4 | |
| SCHEMBL3571206 | 0.71 | ATM (0.46) | ACVRL1ACVR1BMPR1BACVR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2744804-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| EP-2744804-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| EP-2709997-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2016-06-29 | — | — | EP | disclosed |
| US-8889682-B2 | Inhibitors of bruton'S tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889682-B2 | Inhibitors of bruton'S tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889682-B2 | Inhibitors of bruton'S tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-11-18 | — | — | US | disclosed |
| EP-2744804-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-06-25 | — | — | EP | disclosed |
| US-8729078-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729078-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729078-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| EP-2709997-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-20130045965-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2013-02-21 | — | — | US | disclosed |
| WO-2013024078-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | WO | disclosed |
| US-20130045965-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2013-02-21 | — | — | US | disclosed |
| US-20130045965-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2013-02-21 | — | — | US | disclosed |
| US-20120295885-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120295885-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120295885-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2012-11-22 | — | — | US | disclosed |
| WO-2012156334-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295885-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | CHRNA3 4711/4885CHRNB2 4376/4885CHRNA4 4792/4885 |
| US-20130045965-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | CHRNA3 4697/4885CHRNB2 4378/4885CHRNA4 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.